- Home
- EXTR vs HRMY Comparison
EXTR vs HRMY Comparison
Compare EXTR & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXTR
- HRMY
- Stock Information
- Founded
- EXTR 1996
- HRMY 2017
- Country
- EXTR United States
- HRMY United States
- Employees
- EXTR N/A
- HRMY N/A
- Industry
- EXTR Telecommunications Equipment
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- EXTR Telecommunications
- HRMY Health Care
- Exchange
- EXTR Nasdaq
- HRMY Nasdaq
- Market Cap
- EXTR 2.6B
- HRMY 2.1B
- IPO Year
- EXTR 1999
- HRMY 2020
- Fundamental
- Price
- EXTR $22.32
- HRMY $32.39
- Analyst Decision
- EXTR Strong Buy
- HRMY Strong Buy
- Analyst Count
- EXTR 6
- HRMY 9
- Target Price
- EXTR $21.42
- HRMY $55.33
- AVG Volume (30 Days)
- EXTR 1.3M
- HRMY 668.4K
- Earning Date
- EXTR 10-29-2025
- HRMY 10-28-2025
- Dividend Yield
- EXTR N/A
- HRMY N/A
- EPS Growth
- EXTR N/A
- HRMY 58.41
- EPS
- EXTR N/A
- HRMY 3.10
- Revenue
- EXTR $1,140,067,000.00
- HRMY $772,527,000.00
- Revenue This Year
- EXTR $10.26
- HRMY $20.09
- Revenue Next Year
- EXTR $7.48
- HRMY $16.74
- P/E Ratio
- EXTR N/A
- HRMY $10.46
- Revenue Growth
- EXTR 2.05
- HRMY 17.74
- 52 Week Low
- EXTR $10.10
- HRMY $26.47
- 52 Week High
- EXTR $22.89
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- EXTR 63.56
- HRMY 30.32
- Support Level
- EXTR $21.50
- HRMY $32.87
- Resistance Level
- EXTR $22.89
- HRMY $37.05
- Average True Range (ATR)
- EXTR 0.60
- HRMY 1.15
- MACD
- EXTR 0.01
- HRMY -0.60
- Stochastic Oscillator
- EXTR 75.22
- HRMY 1.59
About EXTR Extreme Networks Inc.
Extreme Networks Inc provides AI-powered cloud networking, focused on delivering simple and secure solutions that help businesses address challenges and enable connections among devices, applications, and users. The group designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. It has one reportable segment, the development, marketing, and sale of network infrastructure equipment and related software. The Company operates in three geographical areas: Americas, EMEA, and APAC.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.